A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

Scientists believe that vaccinating the entire global population is the key to contain the ongoing coronavirus disease 2019 (COVID-19) pandemic. This pandemic is caused by the rapid outbreak of a ribonucleic acid (RNA) virus known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immune protection against SARS-CoV-2 To date, several COVID-19 vaccines have received emergency use authorization (EUA) from regulatory agencies in many countries across the world. Some of the vaccines that received EUA are based on adenovirus vectors, messenger ribonucleic acid (mRNA), and nanoparticle technologies. These vaccines target different antigenic forms of the SARS-CoV-2 spike (S) protein to elicit an immune response against SARS-CoV-2. Although COVID-19 vaccines provided hope to contain the pandemic, the emergence of SARS-CoV-2 variants has prolonged the timeline. This is because some SARS-CoV-2 variants can evade the immune responses induced by vaccines or from previous natural infections. The waning of neutralizing antibodies (NAb) produced by the vaccines has...